Our research is focused on sudden cardiac death. We have developed several animal models for studying ventricular arrhythmias, the effects of drugs, and the effects of transgenic target modification. Our aim is simple: to identify the best ways of targeting the pathology and its associated electrophysiological dysfunction that causes cardiac arrhythmias during ischaemic heart disease - still the single largest cause of death in the UK population. We are strong proponents of bioassay, generation of clinically-relevant animal models, and pharmacological interrogation of drug action (concentration-response analysis). We work as a small team, engaging with other teams to pursue specific goals. We are keen to collaborate with the pharmaceutical industry in translational drug discovery research, and also have an interest in safety pharmacology, particularly the development of models for detecting drug-induced torsades de pointes (proarrhythmia).